SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Rodberg James

(Last) (First) (Middle)
C/O SIGHT SCIENCES, INC.
4040 CAMPBELL AVE., SUITE 100

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2023
3. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 699 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) 05/16/2022(1) 05/24/2031 Common Stock 27,500 $10.96 D
Stock Options (Right to Buy) 02/01/2022(2) 02/08/2032 Common Stock 13,100 $17.52 D
Restricted Stock Units (3) (3) Common Stock 22,300 (4) D
Restricted Stock Units (5) (5) Common Stock 3,300(5) (4) D
Explanation of Responses:
1. These options were granted on May 25, 2021 and became exercisable as to 25% of the underlying securities May 16, 2022, with the remainder vesting in 36 substantially equal installments on a monthly basis thereafter, subject to the Reporting Person's continued service to the Company through each such date.
2. These options were granted on February 9, 2022 and vest in 48 substantially equal installments on a monthly basis commencing February 1, 2022, subject to the Reporting Person's continued service to the Company through each such date.
3. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs shall vest in four equal installments on an annual basis from December 1, 2023 through December 1, 2026 subject to the Reporting Person's continued service to the Company through each vesting date. The RSUs have no expiration date.
4. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
5. Reflects a grant of 4,400 RSUs made to the Reporting Person under the 2021 Plan, 1,100 of which vested on January 1, 2023. The remaining 3,300 RSUs shall vest in three equal installments on an annual basis from January 1, 2024 through January 1, 2026 subject to the Reporting Person's continued service to the Company through each vesting date. The RSUs have no expiration date.
Remarks:
Interim Chief Financial Officer Exhibit list: Exhibit 24 - Power of Attorney
/s/ Jeremy Hayden, Attorney-in-Fact for James Rodberg 01/18/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.